[
  {
    "ts": null,
    "headline": "Trump Trade: President to sign EO on DOE, weighing Chevron license extension",
    "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: DEPARTMENT OF EDUCATION: President Donald Trump is expected to sign an executive order Thursday to close the Education Department, fulfilling a yearslong pledge to dismantle the federal agency, the White House confirmed, report Garrett Haake, Nnamdi Egwuonwu and Tyler Kingkade of NBC News. Trump",
    "url": "https://finnhub.io/api/news?id=e8c94c43e7f12c68a0723f0935e4cbe0113347992318662e437240856853583b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742566575,
      "headline": "Trump Trade: President to sign EO on DOE, weighing Chevron license extension",
      "id": 133324235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: DEPARTMENT OF EDUCATION: President Donald Trump is expected to sign an executive order Thursday to close the Education Department, fulfilling a yearslong pledge to dismantle the federal agency, the White House confirmed, report Garrett Haake, Nnamdi Egwuonwu and Tyler Kingkade of NBC News. Trump",
      "url": "https://finnhub.io/api/news?id=e8c94c43e7f12c68a0723f0935e4cbe0113347992318662e437240856853583b"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)",
    "summary": "As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.",
    "url": "https://finnhub.io/api/news?id=d707e8f3b0cc0fa822c090325019c202720f707ddbcc4a275332705e626f8505",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742547929,
      "headline": "Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)",
      "id": 133325382,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.",
      "url": "https://finnhub.io/api/news?id=d707e8f3b0cc0fa822c090325019c202720f707ddbcc4a275332705e626f8505"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics",
    "summary": "Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=04a20663c3b5c3252152e08965c8349fa1d9aca071098d6ace3567837727d3e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742546760,
      "headline": "The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics",
      "id": 133325383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=04a20663c3b5c3252152e08965c8349fa1d9aca071098d6ace3567837727d3e0"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Had a Bad Week. Investors Are Used to It.",
    "summary": "Incyte Had a Bad Week. Investors Are Used to It.",
    "url": "https://finnhub.io/api/news?id=eed75c0438f0083066a4e4de9cfe7de33bb9579b0699b9c9c7216de553746825",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742524200,
      "headline": "Incyte Had a Bad Week. Investors Are Used to It.",
      "id": 134149028,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Incyte Had a Bad Week. Investors Are Used to It.",
      "url": "https://finnhub.io/api/news?id=eed75c0438f0083066a4e4de9cfe7de33bb9579b0699b9c9c7216de553746825"
    }
  }
]